Research map: Twenty-Four Month Effectiveness and Safety of Bictegravir/Emtricitabine/Tenofovir Alafenamide in People With HIV: Real-World Data From the BICSTaR Japan Cohort

Back to the article

Papers in this map

  1. Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials · Paul Edward Sax · 2019 · 775 citations · Cited by this paper
  2. Antimicrobial susceptibility and resistance gene profiles of Prevotella spp. isolated in Oita University Hospital, Japan · 2026 · Related
  3. Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults · Rajesh Tim Gandhi · 2022 · 570 citations · Cited by this paper
  4. A case report of tetanus complicated by multiple cerebral infarcts and iliopsoas hematoma · 2026 · Related
  5. Life expectancy after 2015 of adults with HIV on long-term antiretroviral therapy in Europe and North America: a collaborative analysis of cohort studies · Adam Trickey · 2023 · 540 citations · Cited by this paper
  6. Impact of the antimicrobial stewardship incentive program on antimicrobial supply instability: An interrupted time-series analysis using national drug supply data · 2026 · Related
  7. Adherence to HIV treatment regimens: systematic literature review and meta-analysis · Frederick Lewis Altice · 2019 · 242 citations · Cited by this paper
  8. Mycoplasma genitalium infection and pelvic inflammatory disease: A 12-month prospective study in Japanese women · 2026 · Related
  9. Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial · Jean‐Michel Molina · 2018 · 207 citations · Cited by this paper
  10. Rhino-orbito-cerebral fungal infection associated with mixed Cladosporium halotolerans and Penicillium corylophilum, complicated by internal carotid artery occlusion and ischemic stroke: a case report · 2026 · Related
  11. Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial · David Alain Wohl · 2019 · 168 citations · Cited by this paper
  12. Legionnaire's disease with limbic encephalitis · 2026 · Related
  13. Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial · Hans‐Jürgen Stellbrink · 2019 · 147 citations · Cited by this paper
  14. Effectiveness of oral beta-lactam antibiotics in acute bacterial prostatitis: A retrospective study · 2026 · Related
  15. Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials · Chloe M. Orkin · 2020 · 144 citations · Cited by this paper
  16. Sepsis-like symptoms from parechovirus A type 5 in a neonate: First Japanese case and literature review · 2026 · Related
  17. Weight Change Following Antiretroviral Therapy Switch in People With Viral Suppression: Pooled Data from Randomized Clinical Trials · Kristine Mace Erlandson · 2021 · 121 citations · Cited by this paper
  18. Impact of the “DPC Special Provision” on COVID-19 inpatient case identification in Japanese administrative databases · 2026 · Related
  19. Switching to Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Virologically Suppressed Adults With Human Immunodeficiency Virus · Paul Edward Sax · 2020 · 118 citations · Cited by this paper
  20. Human bacteraemia caused by Pseudomonas plecoglossicida, a fish pathogen of ayu (Plecoglossus altivelis): a case report · 2026 · Related
  21. Real-world adherence and persistence for newly-prescribed HIV treatment: single versus multiple tablet regimen comparison among US medicaid beneficiaries · Joshua Cohen · 2020 · 72 citations · Cited by this paper
  22. Antiretrovirals and Weight Change: Weighing the Evidence · David Alain Wohl · 2024 · 71 citations · Cited by this paper
  23. Switching to Fixed-Dose Bictegravir, Emtricitabine, and Tenofovir Alafenamide (B/F/TAF) in Virologically Suppressed HIV-1 Infected Women: A Randomized, Open-Label, Multicenter, Active-Controlled, Phase 3, Noninferiority Trial · Cissy M Kityo · 2019 · 57 citations · Cited by this paper
  24. Twelve‐month effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide in people with HIV : Real‐world insights from BICSTaR cohorts · Stefan Eßer · 2023 · 53 citations · Cited by this paper
  25. Greater burden of chronic comorbidities and co-medications among people living with HIV versus people without HIV in Japan: A hospital claims database study · Daniel J. Ruzicka · 2018 · 52 citations · Cited by this paper
  26. Real-world efficacy and safety of switching to bictegravir/emtricitabine/tenofovir alafenamide in older people living with HIV · Charlotte-Paige Rolle · 2021 · 52 citations · Cited by this paper
  27. Bictegravir/emtricitabine/tenofovir alafenamide in older individuals with HIV : Results of a 96‐week, phase 3b, open‐label, switch trial in virologically suppressed people ≥65 years of age · Franco Maggiolo · 2022 · 43 citations · Cited by this paper
  28. Long‐term success for people living with HIV : A framework to guide practice · Jeffrey Victor Lazarus · 2023 · 43 citations · Cited by this paper
  29. Treatment Adherence And Persistence Among HIV-1 Patients Newly Starting Treatment · Dionne M. Hines · 2019 · 41 citations · Cited by this paper
  30. Comorbidities and co‐medications among 28 089 people living with HIV: A nationwide cohort study from 2009 to 2019 in Japan · Toshio Naito · 2021 · 38 citations · Cited by this paper
  31. Advanced HIV Infection in Treatment-Naïve Individuals: Effectiveness and Persistence of Recommended 3-Drug Regimens · Karam Mounzer · 2022 · 35 citations · Cited by this paper
  32. Impact of preexisting nucleos(t)ide reverse transcriptase inhibitor resistance on the effectiveness of bictegravir/emtricitabine/tenofovir alafenamide in treatment experience patients · Rafael Esteban Micán · 2022 · 30 citations · Cited by this paper
  33. HIV and Aging: Demographic Change in the Asia-Pacific Region · Rainer Puhr · 2016 · 28 citations · Cited by this paper
  34. Outcomes After Switching to BIC/FTC/TAF in Patients with Virological Failure to Protease Inhibitors or Non-Nucleoside Reverse Transcriptase Inhibitors: A Real-World Cohort Study · Huimin Chang · 2021 · 26 citations · Cited by this paper
  35. Bictegravir/emtricitabine/tenofovir alafenamide ensures high rates of virological suppression maintenance despite previous resistance in PLWH who optimize treatment in clinical practice · Daniele Armenia · 2022 · 25 citations · Cited by this paper
  36. Treatment initiation or switch to BIC/FTC/TAF – real-world safety and efficacy data from two HIV centers in Romania · Oana Săndulescu · 2021 · 20 citations · Cited by this paper
  37. Non-persistence to antiretroviral therapy among adults receiving HIV medical care in the United States · Margaret A. Nyaku · 2018 · 19 citations · Cited by this paper
  38. Bictegravir/emtricitabine/tenofovir alafenamide in patients with genotypic NRTI resistance · Stephen D. Shafran · 2022 · 15 citations · Cited by this paper
  39. Long-term outcomes of bictegravir/emtricitabine/tenofovir alafenamide as first-line therapy and as switch strategy in virologically suppressed persons with HIV: data from the ICONA cohort · Antonella d’Arminio Monforte · 2024 · 11 citations · Cited by this paper

Source: OpenAlex (CC0)